epigallocatechin gallate has been researched along with Parkinsonian Disorders in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, KC; Fang, CH; Li, KY; Lin, YW; Soung, HS; Tsai, CC; Tseng, HC; Wang, MH; Yang, CC | 1 |
| Cao, S; Chen, L; Hu, X; Yang, J; Zhou, W | 1 |
| Al-Amri, JS; Hagras, MM; Mohamed I, M | 1 |
| Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B | 1 |
| Chan, P; Chen, M; Li, X; Li, Y; Wang, P; Wang, T; Yu, S; Yue, F | 1 |
| Amit, T; Kalfon, L; Mandel, SA; Reznichenko, L; Youdim, MB | 1 |
| Jeon, BS; Kim, JM; Kim, JS; O, JJ | 1 |
| Mandel, S; Maor, G; Youdim, MB | 1 |
8 other study(ies) available for epigallocatechin gallate and Parkinsonian Disorders
| Article | Year |
|---|---|
Protective Effect of (-)Epigallocatechin-3-gallate on Rotenone-Induced Parkinsonism-like Symptoms in Rats.
Topics: Animals; Apoptosis; Behavior, Animal; Catechin; Corpus Striatum; Disease Models, Animal; Encephalitis; Inflammation Mediators; Male; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar; Rotenone | 2020 |
Effects and mechanism of epigallocatechin-3-gallate on apoptosis and mTOR/AKT/GSK-3β pathway in substantia nigra neurons in Parkinson rats.
Topics: alpha-Synuclein; Animals; Apoptosis; Catechin; Glycogen Synthase Kinase 3 beta; Male; Neuroprotective Agents; Parkinsonian Disorders; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Substantia Nigra; TOR Serine-Threonine Kinases; Treatment Outcome | 2019 |
Effect of epigallocatechin-3-gallate on inflammatory mediators release in LPS-induced Parkinson's disease in rats.
Topics: Animals; Catechin; Dopamine; Inflammation Mediators; Lipopolysaccharides; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2013 |
Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
Topics: Animals; Antipsychotic Agents; Caffeine; Catalepsy; Catechin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Lipid Peroxidation; Male; Mice; Motor Activity; Parkinsonian Disorders; Tea | 2015 |
Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys.
Topics: alpha-Synuclein; Animals; Catechin; Cell Survival; Corpus Striatum; Dopamine; Dopaminergic Neurons; Female; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra | 2015 |
Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.
Topics: Animals; Antioxidants; Catechin; Cell Line; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Indans; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Neuroprotective Agents; Parkinsonian Disorders; Recovery of Function; Substantia Nigra; Treatment Outcome | 2010 |
Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: Animals; Catechin; Cell Death; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Tea | 2010 |
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apomorphine; Catechin; Disease Models, Animal; Free Radicals; Iron; Iron Chelating Agents; Lewy Bodies; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Substantia Nigra; Synucleins; Ubiquitin | 2004 |